These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7793859)

  • 21. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate.
    Dimmitt DC; Hunt TL; Spalitto AJ; Cramer MB; Shah AK; Arumugham T; Hahne W
    Ann Pharmacother; 1998 Jan; 32(1):39-44. PubMed ID: 9475818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
    Adkison KK; Shachoy-Clark A; Fang L; Lou Y; O'Mara K; Berrey MM; Piscitelli SC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2802-6. PubMed ID: 15980352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
    Zhang KE; Wu E; Patick AK; Kerr B; Zorbas M; Lankford A; Kobayashi T; Maeda Y; Shetty B; Webber S
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1086-93. PubMed ID: 11257019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
    Morse GD; Fischl MA; Shelton MJ; Cox SR; Driver M; DeRemer M; Freimuth WW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):169-74. PubMed ID: 8980774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite.
    Rosser LM; O'Donnell AM; Lee KM; Morse GD
    Antiviral Res; 1994 Dec; 25(3-4):193-200. PubMed ID: 7535991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects.
    Tamaki S; Shibata T; Hunt T; Gerhardt B; Yamada H; Pai SM
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):371-384. PubMed ID: 30779479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).
    Moore KH; Raasch RH; Brouwer KL; Opheim K; Cheeseman SH; Eyster E; Lemon SM; van der Horst CM
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2732-7. PubMed ID: 8593010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose, placebo-controlled, phase I study of oral dolasetron.
    Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
    Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
    Cass LM; Efthymiopoulos C; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():1-11. PubMed ID: 10429835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.
    Anderson RD; Griffy KG; Jung D; Dorr A; Hulse JD; Smith RB
    Clin Ther; 1995; 17(3):425-32. PubMed ID: 7585846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
    Cheeseman SH; Hattox SE; McLaughlin MM; Koup RA; Andrews C; Bova CA; Pav JW; Roy T; Sullivan JL; Keirns JJ
    Antimicrob Agents Chemother; 1993 Feb; 37(2):178-82. PubMed ID: 8452345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.
    Goodwin SD; Gallis HA; Chow AT; Wong FA; Flor SC; Bartlett JA
    Antimicrob Agents Chemother; 1994 Apr; 38(4):799-804. PubMed ID: 8031049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.